Impact of time-of-day on immunochemotherapy efficacy in non–small cell lung cancer

Jun 8, 2026Annals of medicine and surgery (2012)

Time of day may affect how well immune and chemotherapy treatments work in non-small cell lung cancer

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Clinical trials indicate that early-day administration of improves progression-free and overall survival in non-small cell lung cancer (NSCLC).

Non-small cell lung cancer (NSCLC) is primarily driven by genetic changes, including mutations in EGFR, KRAS, and ALK.
Standard treatments for NSCLC include surgery, radiotherapy, platinum-based chemotherapy, and PD-1/PD-L1 immunotherapy, but survival rates remain low.
Emerging evidence suggests that circadian biology may affect the effectiveness of cancer therapies, particularly through time-of-day administration.
influence immune cell movement, the release of signaling molecules, and how drugs are metabolized, which may impact treatment responses.
Chronotherapy benefits have also been noted in other cancers, such as colorectal, breast, pancreatic, and liver cancers, suggesting a wider applicability.

AI simplified

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide. Pathophysiologically, NSCLC arises from genetic alterations such as EGFR, KRAS, and ALK mutations, which drive dysregulated signaling, uncontrolled proliferation, and immune evasion. Standard treatments include surgery, radiotherapy, platinum-based chemotherapy, and immunotherapy with PD-1/PD-L1 inhibitors, yet survival outcomes remain suboptimal. Emerging evidence suggests that circadian biology influences therapeutic efficacy, with time-of-day (ToD) offering a novel approach to optimize outcomes. Mechanistically, regulate immune cell trafficking, cytokine release, and drug metabolism, thereby modulating treatment response and toxicity. Clinical trials in NSCLC demonstrate that early-day administration of immunochemotherapy improves progression-free and overall survival compared to late dosing. Similar chronotherapy benefits have been reported in colorectal, breast, pancreatic, and hepatocellular cancers, underscoring broad translational relevance. Despite promise, challenges include patient heterogeneity in circadian rhythms, logistical barriers in oncology clinics, and limited biomarker validation. Future strategies should prioritize multicenter validation, integration of chronobiological profiling, and exploration of combination therapies. Cost-effectiveness analyses, awareness campaigns, and clinical drives to evaluate safety and adherence will be essential to establish trust and optimize outcomes.